Domestic Firms Play Oral Antiviral Catchup As China Approves Paxlovid

With home-grown 3CL protease inhibitors for COVID-19 still shrouded in uncertainty, some companies in China are now turning to oral RNA polymerase inhibitors as a nearer term option for both mild-to-moderate and severe patients.